Merck & Co., Inc. · MRK · Next earnings

Merck & Co., Inc. reports Thursday, Oct 29, 2026

MRK reports before market open with consensus EPS at $2.22 and revenue at $17.32B. Last quarter: Merck Q1 2026: Revenue Beat and Raised Guidance, But One-Time Charges Weigh on EPS

Reports Before market open39 days awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $2.22 Calendar consensus
Consensus revenue $17.32B Calendar consensus
Report date Oct 29, 2026 Thursday, date estimated
Session Before market open 39 days away

Where MRK left off: FY2026 Q1

Full report

Merck Q1 2026: Revenue Beat and Raised Guidance, But One-Time Charges Weigh on EPS

EPS surprise +12.9% Reported $-1.28 vs $-1.47
Revenue surprise +2.8% Reported $16.29B vs $15.85B
Stock move -1.6% Event window
Subsequent drift +8.7% Up to 20 sessions

Full-year EPS guidance raised from $5.00-$5.15 to $5.04-$5.16, with revenue guidance also increased. Guidance sentiment was raised, reflecting operational strength in oncology and animal health despite one-time acquisition charges.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • One-time $9B charge from Cidara Therapeutics acquisition materially depressed quarterly earnings
  • Gardasil sales declined 22% due to weak demand in China and Japan
  • Keytruda faces a Q3 timing headwind from earlier wholesaler purchase patterns
  • Integration risk and additional one-time charges associated with the pending Terns acquisition (~$5.8B increase in R&D expense)
  • U.S. IRA price-setting and potential loss of Keytruda market exclusivity in 2028-2029

Questions analysts left open

  • Dosing frequency and commercial positioning for MK-3000 in retinal disease
  • Implications of the LITESPARK-012 readout for other WELIREG trials
  • Competitive dynamics of PD-1/VEGF combinations versus rivals
  • FDA acceptance timeline and labeling considerations for enlicitide
  • Performance of animal-health launches and regional vaccine declines

Ask FN2 about MRK next report

Transcript, numbers and history already loaded
What should I watch for in MRK's next earnings report?How did MRK guide last quarter, and is consensus above or below that?Give me the bull and bear case going into MRK earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Get the MRK recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent MRK quarters

All MRK earnings
-1.6%FY2026 Q1

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q1

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.